PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40

FDA Chemotherapy Immunization Hospitals 40

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines.

Immunization 52

Immunization Vaccines 52

Roots Analysis

MAY 21, 2024

Specific inhibitors, which bind to disease-associated proteins and prevent them from functioning abnormally, have demonstrated remarkable therapeutic potential in such diseases. The promise of induced protein degradation as a novel therapeutic modality has attracted considerable attention in the pharmaceutical industry.

Immunization 40

Immunization 40

European Pharmaceutical Review

DECEMBER 27, 2023

This is especially important due to the two unique toxicities of CAR T cells, namely CRS and the neurology toxicities that subsequently received the term immune effector cell- associated neurotoxicity syndrome (ICANS). This is in addition to its considerable price tag. Journal of Hematology & Oncology. Annals of Oncology.

Adverse Reactions 82

Adverse Reactions Immunization Medical Schools Chemotherapy 82